Tag: Luminor
First results of SOL Japan highlight “extraordinary performance” of Luminor DCB...
iVascular has announced that "outstanding" results from the SOL Japan study were recently presented at the Japan Endovascular Treatment (JET) conference (14–16 June, Fukuoka,...
Five-year RCT data provide upbeat message on Luminor paclitaxel-coated balloon’s safety...
NOTE: This video is ONLY available to watch in selected countries and geographies
The EffPac trial was a prospective, multicentre, randomised controlled trial (RCT)...
EffPac trial highlights “amazing five-year results” for Luminor DCB
NOTE: This video is ONLY available to watch in selected countries and geographies
Ulf Teichgräber (Jena, Germany) talks to Vascular News at the Cardiovascular and Interventional...
Positive Luminor DCB data from EffPac and TINTIN trials presented at...
New clinical evidence for the use of the Luminor drug-coated balloon (DCB; iVascular) in complex lesions with long-term follow-up has been presented on the...
LINC 2021: Long-term data show sustained efficacy and safety of paclitaxel...
A key theme among the late-breaking trial data presented at LINC 2021 (The Leipzig Interventional Course; 25–29 January, online) was the emergence of long-term...
MERLION trial six-month outcomes presented at VIVA late-breaking trial session
Six-month clinical outcomes of the MERLION trial were presented as part of the VIVA Late-Breaking Clinical Trials Livesteam (25 June), by Tjun Tang (Singapore...
Luminor DCB now reimbursed in France
It was recently announced that luminor 18 and luminor 35 DCBs (iVascular), are now listed on the French LPPR list for de novo lesions...
Experts discuss latest results from EFFPAC and TINTIN trials presented at...
NOTE: ONLY intended for healthcare professionals outside of the USA.
Ulf Teichgräber (Jena, Germany) and Koen Deloose (Dendermonde, Belgium) discuss the 24-month results of the...
Two-year trial data show “astonishing results” for luminor DCB
Ulf Teichgräber (Jena, Germany), talks to Vascular News at EuroPCR 2019 about the EFFPAC trial which compared the luminor (iVascular) drug-coated balloon (DCB) with...
CX 2018: Ulf Teichgräber discusses EffPAC trial 12-month results
Ulf Teichgräber, Jena, Germany, discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018
iVascular initiates TINTIN Luminor trial
iVascular SLU has announced the initiation of the TINTIN trial, evaluating the combined therapy of Luminor drug-coated balloon (DCB) and iVolution self-expandable stent.
The TINTIN...
Luminor drug-coated balloon receives Canadian Medical Device Licence
iVascular has announced that its Luminor 14m peripheral balloon catheter with paclitaxel elution has received the Canadian Medical Device Licence (MDL).
Luminor 14m is a...
Luminor EffPAC study shows efficacy at six months
Data have been announced demonstrating the efficacy of iVascular’s Luminor drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) at six months. The...
LUMINOR Registry may help “reopen the door” for drug-coated balloons below...
The LUMINOR Registry is a real-world prospective multicentre study evaluating iVascular’s Luminor paclitaxel-eluting balloon for treating advanced limb ischaemia. Vascular News spoke to Vincent...
